



2023 AGS BEERS CRITERIA® FOR POTENTIALLY INAPPROPRIATE MEDICATION USE IN OLDER ADULTS

Expert Panel Disclosures

Conflict of Interest (as of June 7, 2023)

- Drs. Brandt, Digmann, DuBeau, Dombrowski, Flanagan, George, Harrington, Hines, Hollmann, Laird, and Steinman had no conflicts to disclose. Dr. Beizer is a consultant to LexiComp, Inc., a Wolters-Kluwer company. Dr. Fick is a consultant for Precision Health Economics. Dr. Holmes receives grant funding from Blue Cross/Blue Shield for a study on deprescribing. Dr. Linnebur is a Committee Member for both the Colorado Access Pharmacy and Therapeutics Committee and the CVS Pharmacy and Therapeutics Committee and has received honoraria from Springer Nature and Merck Manuals. Dr. Semla is a consultant to UnitedHealthcare and to LexiComp, Inc., a Wolters-Kluwer company; his spouse holds shares of Abbvie and Abbott stock.

Author Contributions

All panel members contributed to the concept and design, acquisition of subjects and/or data, analysis, and interpretation of data, and preparation of the manuscript.

Sponsor's Role

AGS staff participated in the final technical preparation and submission of the manuscript.

Objectives

- Understand commonly used medications that should be avoided in the elderly.
- Understand how to use the 2023 AGS Beers Criteria® list in clinical decision making.

Mark H Beers, MD 1954-2009



“A ballet-dancing opera critic who hiked the Alps and took up rowing after diabetes cost him his legs”

- MD, Univ of Vermont
- First med student to do a geriatrics elective at Harvard’s new Division on Aging
- Geriatric Fellowship, Harvard
- Faculty, UCLA/RAND
- Co-editor, Merck Manual of Geriatrics
- Editor in Chief, Merck Manuals

Beers Criteria: History and Utilization

- Original 1991 – Nursing home pts
- Updates
 - 1997 -- All elderly; adopted by CMS in 1999 for nursing home regulation
 - 2003 -- Era of generalization to Med D, then NCQA, HEDIS
 - 2012 -- First Updated AGS Beers Criteria[®] Released, Further adoption into quality measures
 - 2015 – Updated AGS Beers Criteria[®] , added Tables 5 (DDI) and Tables 6 (Renal Dosage Table)
 - 2019 – Updated AGS Beers Criteria[®]

Original Purpose of the 1991 Original Beers Criteria

- Evaluate inappropriate Rx used in NH residents in “common” situations, but under “certain circumstances” might be appropriate
- Clinical research on use of Potentially Inappropriate medications (PIMs)
- QA/QI
- Education of students, residents

Purpose of the AGS Beers Criteria[®]

- To identify drugs that are potentially inappropriate in older adults:
 - 1) Independent of diagnosis
 - 2) Considering diagnosis
 - 3) Drug-drug interactions
 - 4) Renal dosage considerations.
- To reduce adverse drug events and drug related problems and improve medication selection and medication use in older adults
- Designed for use in any clinical setting, also used as an educational, quality and research tool

2023 AGS Beers Criteria[®] Update

Aim:

Update 2019 AGS Beers Criteria[®]

Strategy:

1. Incorporate new evidence
2. Grade the evidence
3. Use an interdisciplinary panel with consensus
4. Incorporate exceptions

Methods

- Expert panel
 - 12 voting members, 3 non-voting members
- Literature search
 - Evidence tables prepared, rated quality of evidence and strength of recommendation
- Followed IOM 2011 recommendations on guideline development
 - Includes period for public comment & invited peer review

Panel Members, Voting Members


- Todd P. Semla, PharmD, MS, BCPG, FCCP, AGSF (Co-Chair)
- Michael Steinman, MD, AGSF (Co-Chair)
- Judith Beizer, PharmD, BCGP, FASCP, AGSF
- Nicole Brandt, PharmD, MBA, BCPP, BCGP, FASCP
- Catherine E. DuBeau, MD
- Donna Fick, PhD, RN, FGSA, AGSF, FAAN
- Nina Flanagan, PhD, GNP-BC, APHM-BC
- Claudene George, MD, MS, RPh
- Holly Holmes, MD, MS, AGSF
- Peter Hollmann, MD, AGSF
- Rosemary Laird, MD, MHSA, AGSF
- Sunny Linnebur, PharmD, FCCP, BCPS, BCGP, FASCP

Panel Members, Non-voting

- Robert Dombrowski, PharmD (CMS)
- Rachel Digmann, PharmD, Pharmacy Quality Alliance (PQA)
- Rachel Harrington, PhD, National Committee for Quality Assurance (NCQA)
- AGS Staff
 - Laura Banks
 - Elvy Ickowicz, MPH
 - Mary Jordan Samuel
- Others
 - Sue Radcliff (research)
 - Susan Aiello, DVM (medical editor)
 - Jirong Yue, MD (research)

Assembling the Evidence

SEARCH TERMS: ADE, inappropriate drug use, med errors, polypharmacy x age/human/English



Designations of Quality of Evidence

Quality of Evidence Grading –

Adapted from ACP Guideline Grading System, GRADE

- High Quality of Evidence
- Moderate Quality of Evidence
- Low Quality of Evidence

Strength of Recommendation

Strong

Harms, adverse events, and risks clearly outweigh the benefits.

Weak

Harms, adverse events, and risks may not outweigh the benefits.

Not included in AGS Beers Criteria®

- Drugs with risks not unique to elderly
 - Purpose is for PIMs specific to elderly
- Not intended to be used for people in hospice or nearing the end of life
- Drugs considered to be low-usage

Limitations

- Evidence base available
- What's not covered
 - Therapeutic duplication
- Special populations within geriatrics
- Search strategy - missed information
- Needs to be applied to circumstances of individual patient, including with shared decision-making

Key Principles on How To Use the AGS Beers Criteria®

- Medications in the AGS Beers Criteria® are potentially inappropriate, not definitely inappropriate.
- Read the rationale and recommendations statements. The caveats and guidance listed are important.
- Understand why medications are included in the AGS Beers Criteria®, and adjust your approach to those medications accordingly.

More Key Principles on How To Use the AGS Beers Criteria®

- Access to meds in the AGS Beers Criteria® should not be excessively restricted by prior authorization and/or health plan coverage policies
- The AGS Beers Criteria® are not equally applicable to all countries

Optimal application of the AGS Beers Criteria® involves identifying potentially inappropriate medications, and where appropriate offering safer non-pharmacologic and pharmacologic therapies

Uses of the AGS Beers Criteria[®] in Clinical Care

Quality Prescribing

- Patient-centered
- Patient-specific goals
- Shared decision-making
- Tolerance for deviation from EBM care guidelines
- Benefits from system-level approaches

Quality Performance Measurement

- Population-centered
- Benchmark goals
- Less ability to account for exceptions for deviation from EBM care guidelines
- Requires system-level approaches

AGS Beers Criteria® only Part of Quality Prescribing

- Quality prescribing includes
 - Correct drug for correct diagnosis
 - Appropriate dose (label; dose adjustments for comorbidity, drug-drug interactions)
 - Avoiding underuse of potentially important medications (e.g., bisphosphonates for osteoporosis)
 - Avoiding overuse (e.g., antibiotics)
 - Avoiding potentially inappropriate drugs
 - Avoiding withdrawal effects with discontinuation
 - Consideration of cost
 - Consideration of shared decision-making throughout care of patient

Perceived Barriers to Appropriate Prescribing

- Polypharmacy, can't review such a long list
- “Best” drugs may cost too much
- Worrying about drug interactions if making drug changes
- Time involved
- Difficulty communicating with patient's other prescribing clinicians
- Lack of knowledge of AGS Beers Criteria®
- Lack of therapeutic alternatives
- Patient unwillingness to change
- Discomfort changing a med another clinician prescribed

Challenges of Using the AGS Beers Criteria in Clinical Care

- All of the above perceived barriers
- RN/Family Request
- Lack of Tested Non Drug Alternatives
- Multiple prescribers
- Risk of drug is less than risk of condition
- Hospice or End-of-Life Care and other special cases and populations

Challenges of Deprescribing

- communication gaps & misunderstandings,
- patient reluctance/fear of stopping,
- coordination among clinicians,
- dosage tapering,
- withdrawal symptoms,
- conveying stop orders to pharmacies
- and more!

Assistance in deprescribing:

- <https://deprescribing.org/resources/>
- <https://www.deprescribingnetwork.ca/professionals>

New to the 2023 Update

- Removed drugs considered to be low-usage
 - Defined low use as <4000 U.S. Medicare beneficiaries aged 65 years or older receiving the drug in 2020 based on data from Medicare Part D Public Use Files
 - Drugs removed due to low-usage are still considered potentially inappropriate
 - An online appendix compiling all drugs removed from all previous AGS Beers Criteria[®], accessible via the JAGS article
- Section on deprescribing and helpful resources

AGS Beers Criteria[®] Tables

- Table 2 – PIM list (with some selective caveats)
- Table 3 – PIMs due to Drug – Disease/Syndrome Interaction
- Table 4 – Medications to be used with caution
- Table 5 – Potentially Clinically Important Drug–Drug Interactions
- Table 6 – Medications that should be avoided or have dosage reduced with varying levels of kidney function
- Table 7 – Drugs with strong anticholinergic properties
- Table 8 – Medications Removed
- Table 9 – Medications Added
- Table 10 – Medications Moved or Modified

Table 2. Potentially Inappropriate Medications

Organ System or TC or Drug	Rationale	Recommend.	QoE	SoR
Aspirin for primary prevention of cardiovascular disease	<p>Risk of major bleeding from aspirin increases markedly in older age. Studies suggest lack of net benefit and potential for net harm when initiated for primary prevention in older adults. There is less evidence about stopping aspirin among long-term users, although similar principles as for initiation may apply.</p> <p><i>Note:</i> Aspirin is generally indicated for secondary prevention in older adults with established cardiovascular disease.</p>	Avoid initiating aspirin for primary prevention of cardiovascular disease. Consider deprescribing aspirin in older adults already taking it for primary prevention.	High	Strong
Antipsychotics (conventional or atypical)	Increase CVA risk; increased cognitive decline and mortality in dementia	Avoid unless danger to self/others and non pharm has failed	Moderate	Strong
Benzodiazepines Short and long acting	Risk cognitive effects and injury (fall/MVA); may be appropriate, eg EtOH withdrawal	Avoid	Moderate	Strong

Table 2. Potentially Inappropriate Medications

Organ System or TC or Drug	Rationale	Recommendation	QoE	SoR
<p>Estrogens with or w/o progestins (includes natural and synthetic estrogen preparations)</p>	<p>Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women.</p> <p>For women who start HRT at age 60 and older, the risks of HRT are greater than the benefits, as HRT is linked to a higher risk of heart disease, stroke, blood clots, and dementia.</p> <p>Evidence indicates that vaginal estrogens for the treatment of vaginal dryness are safe and effective; women with a history of breast cancer ... are advised to discuss the risks and benefits of low-dose vaginal estrogen with their healthcare provider.</p>	<p>Do not initiate systemic estrogen (e.g., oral tablets or transdermal patch). Consider deprescribing among older women already using this medication. Vaginal cream or tablets: acceptable to use low-dose for management of dyspareunia, recurrent lower UTIs, and other vaginal symptoms.</p>	<p>Oral and patch: high</p> <p>Vaginal crm/tab: moderate</p>	<p>Oral and patch: strong</p> <p>Vaginal crm/tab : weak</p>

Table 2. Potentially Inappropriate Medications

Organ System or TC or Drug	Rationale	Recommendation	QoE	SoR
Sulfonylureas, (all, including short- and longer-acting)	<p>Sulfonylureas have a higher risk of cardiovascular events, all-cause mortality, and hypoglycemia than alternative agents. Sulfonylureas may increase the risk of cardiovascular death and ischemic stroke.</p> <p>Long-acting agents (e.g., glyburide, glimepiride) confer higher risk of prolonged hypoglycemia than short-acting agents (e.g., glipizide).</p>	<p>Avoid sulfonylureas as first- or second-line monotherapy or add-on therapy unless there are substantial barriers to use of safer and more effective agents. If a sulfonylurea is used, choose short-acting agents (e.g., glipizide).</p>	<p>Hypoglycemia: High.</p> <p>CV events and all-cause mortality: Moderate.</p> <p>CV death and ischemic stroke: Low</p>	Strong
Skeletal Muscle Relaxants	<p>Muscle relaxants typically are poorly tolerated by older adults due to anticholinergic adverse effects, sedation, increased risk of fractures; effectiveness at doses tolerated by older adults questionable.</p> <p>Does not apply to skeletal muscle relaxants used for management of spasticity (i.e., baclofen and tizanidine) although these drugs can also cause substantial adverse effects.</p>	Avoid	Moderate	Strong

Table 2. Potentially Inappropriate Medications

Organ System or TC or Drug	Rationale	Recommendation	QoE	SoR
Rivaroxaban for long-term treatment of nonvalvular atrial fibrillation or (VTE)	At doses used for long-term treatment of VTE or nonvalvular atrial fibrillation, rivaroxaban appears to have higher risk of major bleeding and GI bleeding in older adults than other DOACs, particularly apixaban. Rivaroxaban may be reasonable in special situations, e.g., when once-daily dosing is necessary.	Avoid for long-term treatment of atrial fibrillation or VTE in favor of safer anticoagulant alternatives.	Moderate	Strong
Warfarin	Compared with DOACs, warfarin has higher risks of major bleeding (particularly intracranial bleeding) and similar or lower effectiveness for treatment of nonvalvular atrial fibrillation and VTE. DOACs are thus the preferred choice for anticoagulation for most people with these conditions.	Avoid starting warfarin as initial therapy for treatment of nonvalvular atrial fibrillation or VTE unless DOACs are contraindicated or there are substantial barriers to their use. For older adults with stable INRs (i.e., >70% time in therapeutic range) and no adverse effects with warfarin, it may be reasonable to continue.	High	Strong

Summary of Warfarin, Rivaroxaban & Dabigatran

Synthesis of anticoagulation recommendations	
Explanation	Recommendation
<p>This criterion summarizes recommendations for warfarin (Table 2), rivaroxaban (Table 2), and dabigatran (Table 4) — anticoagulants to avoid or to use with caution. A “use with caution” recommendation reflects less concern and/or less clear evidence than an “avoid” recommendation. See individual criteria on these medications for more information about anticoagulant-related recommendations.</p> <p>When selecting among DOACs and choosing a dosage, pay special consideration to kidney function (see Table 6), indication, and body weight.</p>	<p>Warfarin: <i>Avoid</i> starting warfarin as initial therapy for treatment of venous thromboembolism (VTE) or nonvalvular atrial fibrillation unless alternative options (e.g., DOACs) are contraindicated or there are substantial barriers to their use. For older adults who have been using warfarin long-term, it may be reasonable to continue this medication, particularly among those with well-controlled INRs (i.e., >70% time in therapeutic range) and no adverse effects.</p>
	<p>Rivaroxaban: <i>Avoid</i> rivaroxaban for long-term treatment of nonvalvular atrial fibrillation or VTE in favor of safer anticoagulant alternatives.</p>
	<p>Dabigatran: <i>Use caution</i> in selecting dabigatran over other DOACs (e.g., apixaban) for long-term treatment of nonvalvular atrial fibrillation or VTE.</p>

Table 3. Drug-disease/syndrome Interactions

Disease or Syndrome	Drug	Rationale	Recommendation	QoE	SoR
Delirium	Anticholinergics Antipsychotics Benzodiazepines Corticosteroids (oral and parenteral) H2-receptor antagonists <ul style="list-style-type: none"> • Cimetidine • Famotidine • Nizatidine Z-drugs <ul style="list-style-type: none"> • Eszopiclone • Zaleplon • Zolpidem Opioids	Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium. Antipsychotics: Corticosteroids Opioids	Avoid, except in situations listed under rationale statement.	H2-receptor antagonists – Low. All others – Moderate	Strong

Table 3. Drug-disease/syndrome Interactions

Disease or Syndrome	Drug	Rationale	Recommendation	QoE	SoR
Dementia or cognitive impairment	<p>Anticholinergics</p> <p>Antipsychotics, chronic use or persistent as-needed</p> <p>Benzodiazepines</p> <p>Z-drugs</p> <ul style="list-style-type: none"> • Eszopiclone • Zaleplon • Zolpidem 	<p>Avoid because of adverse CNS effects. See criteria on individual drugs for additional information.</p> <p>Antipsychotics: increased risk of stroke and greater rate of cognitive decline and mortality in people with dementia. Avoid for behavioral problems... unless documented non-pharm options have failed and/or patient is threatening self or others.</p>	<p>Avoid</p> <p>If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.</p>	Moderate	Strong

Table 4. Use With Caution

- Drugs marked “Use With Caution” do not carry the same weight as the main criteria, i.e., not marked “Avoid”
- Some signal of harm or concern is present, but:
 - the evidence, balance of benefits of harms, and/or clinical applicability is insufficiently strong to merit inclusion in the main criteria, or
 - may not outweigh the drug’s potential benefit.

Table 4. Use with Caution

Drug	Rationale	Recommendation	QoE	SoR
Dabigatran for long-term treatment of nonvalvular afib or VTE	Increased risk of GI bleeding compared with warfarin and of GI bleeding and major bleeding compared with apixaban in older adults when used for long term treatment of nonvalvular atrial fibrillation or VTE	Use caution in selecting dabigatran over other DOACs (e.g., apixaban) for long-term treatment of nonvalvular atrial fibrillation or VTE.	Moderate	Strong
Dextromethorphan-Quinidine	Limited efficacy in patients w/behavioral symptoms of dementia. May increase falls and concerns w/DDIs and with use in those with heart failure	Use with caution	Moderate	Strong

Table 4. Use with Caution

Drug	Rationale	Recommendation	QoE	SoR
Ticagrelor (added to prasugrel)	Increase the risk of major bleeding in older adults compared with clopidogrel, especially among those 75 years old and older. However, this risk may be offset by CV benefits in select patients.	Use with caution, particularly in adults 75 years old and older. If prasugrel is used, consider lower dose (5 mg) for those 75 years old and older.	Moderate	Strong
SGLT2 Inhibitors	Older adults may be at increased risk of: Urogenital infections, particularly women in the 1st month of treatment. Euglycemic DKA	Use with caution. Monitor patients for urogenital infections and ketoacidosis.	Moderate	Weak

Table 5. Drug–Drug Interactions That Should Be Avoided in Older Adults

Object Drug and Class	Interacting Drug and Class	Risk Rationale	Recommendation	QoE	SoR
Opioids	Benzodiazepines	Increased risk of overdose and adverse events.	Avoid.	Moderate	Strong
Opioids	Gabapentin Pregabalin	Increased risk of sedation-related adverse events; including respiratory depression and death	Avoid; except when transitioning from opioids, or when using gabapentinoids to reduce opioid dose. Caution should be used in all circumstances.	Moderate	Strong
Anticholinergic	Anticholinergic	Use of more >1 drug w/ anti-cholinergic properties increases risk of cog. decline, delirium, and falls/fractures.	Avoid, minimize number of anticholinergic drugs (Table 7)	Moderate	Strong

Table 5. Drug–Drug Interactions That Should Be Avoided in Older Adults

Object Drug and Class	Interacting Drug and Class	Risk Rationale	Recommendation	QoE	SoR
Antiepileptics (including gabapentinoids) Antidepressants (TCAs, SSRIs, and SNRIs) Antipsychotics Benzodiazepines Nonbenzodiazepine benzodiazepine receptor agonist hypnotics (i.e., “Z-drugs”) Opioids Skeletal muscle relaxants	Any combination of 3 of these CNS-active drugs	Increased risk of falls and of fracture with the concurrent use of 3 CNS-active agents	Avoid concurrent use of ≥3 CNS-active drugs (among types as listed at left); minimize number of CNS-active drugs.	High	Strong

Table 6. Medications That Should Be Avoided or Have Their Dosage Reduced Due to Kidney Function in Older Adults

Medication Class and Medication	CrCL, mL/min, at Which Action Required	Rationale	Recommendation	QoE	SoR
Cardiovascular and antithrombotics					
Dabigatran	<30	Lack of evidence for efficacy and safety in individuals with a CrCl <30 mL/min. Label dose when CrCl 15–30 mL/min based on PK data.	Avoid when CrCl <30mL/min; dose adjustment advised when CrCl >30 mL/min in the presence of DDIs.	Moderate	Strong
Edoxaban	15–50 <15 or >95	Lack of evidence of efficacy or safety in patient's w/ a CrCl <30 mL/min	Reduce dose Avoid	Moderate	Strong
Rivaroxaban	<50	Lack of efficacy or safety evidence when CrCl <15 mL/min; limited evidence for CrCl 15–30 mL/min.	Avoid if CrCl <15 mL/min. Reduce dose if CrCl 15–50 mL/min follow manufacturer labeled dosing.	Moderate	Strong

Table 6. Medications That Should Be Avoided or Have Their Dosage Reduced

Medication Class and Medication	CrCL, mL/min, at Which Action Required	Rationale	Recommendation	QoE	SoR
Central nervous system and analgesics					
Baclofen	eGFR <60	Increased risk of encephalopathy requiring hospitalization in older adults with eGFR <60 mL/min or who require chronic dialysis.	Avoid baclofen in older adults with impaired kidney function (eGFR <60 mL/min). When baclofen cannot be avoided, use the lowest effective dose and monitor for signs of CNS toxicity, including altered mental status.	Moderate	Strong
NSAIDs	<30	May increase risk of acute kidney injury and further decline of kidney function.	Avoid	Moderate	Strong

Take homes


- Don't let the perfect be the enemy of the good
- The AGS Beers Criteria[®] is only part of appropriate prescribing
- Target initiatives to high prevalence/high severity meds (based on local data, where possible)
- Shared decision-making in selecting and changing treatment regimens is critical.
- Stopping meds should be done with same consideration as starting
- AGS Beers Criteria[®] = Patient-centered care

AGS Beers Criteria[®] Resources

- Updated 2023 AGS Beers Criteria[®] Pocket Card and App
- How to Use the American Geriatrics Society 2015 Beers Criteria—A Guide for Patients, Clinicians, Health Systems, and Payors (JAGS 2015)
- Using Wisely: A Reminder on the Proper Use of the American Geriatrics Society Beers Criteria[®] (JAGS 2019)
- Alternative Medications List (Coming Soon)

2023 AGS Updated Beers Criteria® App

\$9.99 per
year



AGS BEERS CRITERIA® 2023 **AGS Beers Criteria®**
Medications and Older Adults

OPEN

9 RATINGS: 4.4 (★★★★☆) | AGE: 17+ (Years Old) | CATEGORY: Medical | DEV: America


What's New | [Version History](#)
Version 1.1.0.83 | 1w ago
Updated 2023 AGS Beers Criteria® content

Preview

2:35: SEARCH for medications

2:49: Drugs to Use with Caution

- Antipsychotics
- Canagliflozin
- Carbamazepine (selected Antiepileptics)
- Dabigatran for long-term treatment of atrial fibrillation or thromboembolism (VTE)
- Dapagliflozin



AGS BEERS CRITERIA®

SEARCH for medications

Search for generic drug name or category

2023 AGS Beers Criteria® for Potentially Inappropriate Medications (PIMs) for Older Adults






- PIMs in Older Adults
- PIMs for Older Adults with Specific Disease or Syndrome
- Drugs to Use with Caution

HOME | SEARCH | BOOKMARKS

AGS Beers Criteria®: Tables


- Table 2: Medications considered as potentially inappropriate
- Table 3: Medications potentially inappropriate in patients with certain diseases or syndromes
- Table 4: Medications to be used with caution
- Table 5: Potentially inappropriate drug-drug interactions
- Table 6: Medications whose dosages should be adjusted based on renal function

J Am Geriatr Soc 2023;1-30 <https://doi.org/10.1111/jgs.18372>

	PIMs in Older Adults >
	PIMs for Older Adults with Specific Disease or Syndrome >
	Drugs to Use with Caution >
	Drug - Drug Interactions >
	PIMs Due to Reduced Kidney Function >

Laminated Pocket Card

<https://geriatricscareonline.org/ProductAbstract/2023-ags-beers-criteria-pocketcard/PC0015>





To access the AGS Beers Criteria[®] Resources Visit

www.geriatricscareonline.org

AGS